Eli Lilly Cleared Two More Trials For Its Next-Generation Obesity Drug. It Will Seek FDA Approval Next Year

Source: International Business Times

After 80 weeks of treatment, obese, non-diabetic participants receiving retatrutide lost an average of 22. 6% of their body weight, while also showing improvements in several cardiometabolic risk factors. Scott Olson/Getty Images Eli Lilly said Thursday it plans to seek regulatory approval in the first quarter of 2027 for its experimental obesity drug retatrutide after the treatment cleared two additional late-stage clinical trials.